Elicio Therapeutics Q2 net loss narrows as R&D expenses fall
Elicio Therapeutics Inc expected to post a loss of 54 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Datadog, Terawulf, Paychex
Elicio shares slide after pancreatic cancer vaccine falls short in mid-stage study (updated)
U.S. STOCKS ON THE MOVE-Datadog, Terawulf
Elicio shares tumble after pancreatic cancer therapy misses mid-stage study goal
U.S. STOCKS ON THE MOVE-Crypto Stocks, Travel Stocks, Micron
Elicio Therapeutics tumbles as pancreatic cancer vaccine misses main goal of trial
NASDAQ RESUMED AT 07:35 AM
Brief: Elicio Therapeutics Reports Results From Phase 2 AMPLIFY-7P Study And Outlines Refined Phase 3 Development Strategy For ELI-002 7P In Adjuvant Pancreatic Cancer
NASDAQ TRADE HALT HALT NEWS PENDING AT 06:55 AM
U.S. RESEARCH ROUNDUP- Datadog, Eli Lilly, Oracle
Elicio Therapeutics Q1 net loss widens, cash runway extends into Q4 2026
Brief: Elicio Therapeutics To Issue Up To $400 Million In Securities
Elicio Therapeutics Q3 net loss narrows, cash runway extended
Brief: Elicio Therapeutics Reports Robust, Cytolytic mKRAS-Specific T Cell Responses Across Diverse Patient HLA in Ongoing Phase 2 AMPLIFY-7P Trial of ELI-002 7P and New ELI-004 Preclinical Data at SITC
Brief: Elicio Therapeutics Reports Robust T Cell Responses Across Diverse HLA Backgrounds In Ongoing Phase 2 Amplify-7P Trial
Elicio Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Elicio Therapeutics Inc expected to post a loss of 51 cents a share - Earnings Preview